Neurocrine Biosciences Inc (NAS:NBIX)
$ 126.59 -1.32 (-1.03%) Market Cap: 12.82 Bil Enterprise Value: 11.84 Bil PE Ratio: 33.94 PB Ratio: 4.71 GF Score: 85/100

Neurocrine Biosciences Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 02:55PM GMT
Release Date Price: $93.81 (+0.78%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Hi, everyone. Welcome back. I'm Brian Abrahams, Senior Biotech Analyst at RBC Capital Markets. Our next presenting company is Neurocrine. And from Neurocrine we have their CFO, Matt Abernethy; and their CMO, Eiry Roberts. Thanks Matt and Eiry. Really appreciate you joining us.

Eiry Wyn Roberts
Neurocrine Biosciences, Inc. - Chief Medical Officer

Great to be here.

Matthew C. Abernethy
Neurocrine Biosciences, Inc. - CFO

Thanks, Brian. Really glad to be here.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Really glad to have to you guys. So let's maybe start on the commercial side with INGREZZA. You guys are coming off of a quarter where you faced some change, particularly related to COVID, but also provided some encouraging metrics. Near term, what are you seeing that gives you the most confidence in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot